Group 1 - The core viewpoint of the article is that Xinhua Medical has decided to reduce its stake in Huajian Medical due to various uncertainties, including trading volume, liquidity, and regulatory rules [2] Group 2 - Xinhua Medical's decision to divest was influenced by the trading volume and liquidity of Huajian Medical [2] - The company also considered regulatory rules as a factor in its decision-making process [2]

Group 1 - The core viewpoint of the article is that Xinhua Medical has established a rehabilitation equipment exhibition room in its industrial park and is conducting external promotion, with expectations of generating revenue from some rehabilitation products by 2025 [2] Group 2 - The company is actively engaging with investors through an interactive platform to provide updates on its initiatives [2] - The establishment of the exhibition room indicates a strategic move towards enhancing visibility and market presence in the rehabilitation equipment sector [2] - The anticipated revenue generation from rehabilitation products by 2025 suggests a positive outlook for the company's future financial performance [2]

Group 1 - The core viewpoint of the article is that Xinhua Medical has obtained four medical device registration certificates in December, enhancing its product lines in blood dialysis and in vitro diagnostics, which aligns with the company's main business layout and is expected to improve its competitiveness [1] Group 2 - The newly acquired registration certificates are expected to enrich the company's offerings in the blood dialysis product line [1] - The addition of these products is in line with the company's strategic focus and is anticipated to strengthen its market position [1]

Core Viewpoint - Xinhua Medical has actively engaged with investors through exhibitions and facility tours, showcasing its medical linear accelerators and core technologies [1] Group 1 - The company has set up a showroom in its industrial park to display medical linear accelerators [1] - Xinhua Medical participated in exhibitions where it showcased its medical linear accelerators and provided on-site explanations of core technologies [1] - The company organized multiple on-site visits for investors throughout the year, allowing them to tour the production workshop [1]

（编辑 丛可心） 证券日报网讯 12月29日，新华医疗在互动平台回答投资者提问时表示，公司积极与投资者进行沟通交 流，搭建沟通桥梁，通过邀请投资者实地调研、线上路演等方式，与投资者实现直接对话交流，建立了 良好的互动关系。 ...

证券之星消息，截至2025年12月29日收盘，新华医疗(600587)报收于14.54元，下跌0.82%，换手率 0.62%，成交量3.76万手，成交额5487.47万元。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 12月29日的资金流向数据方面，主力资金净流出92.65万元，占总成交额1.69%，游资资金净流出98.89 万元，占总成交额1.8%，散户资金净流入191.54万元，占总成交额3.49%。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 新华医疗2025年三季报显示，前三季度公司主营收入69.78亿元，同比下降6.0%；归母净利润4.34亿 元，同比下降29.61%；扣非净利润3.7亿元，同比下降38.98%；其中2025年第三季度，公司单季度主营 收入21.88亿元，同比下降2.2%；单季度归母净利润4859.29万元，同比下降63.39%；单季度扣非净利润 3766.15万元，同比下降71.77%；负债率45.85%，投资收益4828.2 ...

证券代码：600587 证券简称：新华医疗 公告编号：临2025-067 山东新华医疗器械股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购注销原因：根据公司《2021 年限制性股票激励计划（草案）》（以下 简称"《激励计划》"）的相关规定，原授予限制性股票的激励对象孙士磊等 4 人发生工作调动，刘杰等 2 人退休，上述共 6 人不再符合激励条件，公司拟对该 激励对象已获授但尚未解除限售的限制性股票合计 33,370 股进行回购并注销。 本次注销股份的有关情况 | 回购股份数量（股） | 注销股份数量（股） | 注销日期 | | | | --- | --- | --- | --- | --- | | 33,370 | 33,370 | 2026 年 1 | 月 | 5 日 | 一、本次限制性股票回购注销的决策与信息披露 1、2025 年 10 月 29 日，公司召开第十一届董事会第二十二次会议，审议通 过了《关于调整 2021 年限制性股票激励计划回购价格及回购数量的议案》和《关 于回购注 ...

北京市东城区 北三环东路 36 号环球贸易中 心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 关 于 山 东 新 华 医 疗 器 械 股 份 有 限 公 司 回 购 注 销 2021 年 限 制 性 股 票 激 励 计 划 部 分 限 制 性 股 票 及 调 整 回 购 价 格 与 回 购 数 量 之 法 律 意 见 书 君致（ 法 ）字[2025]295 号 北 京 市 君 致 律 师 事 务 所 北京市东城区北三环东路 36 号环球贸易中心 B 座 11 层 邮编(100013) Add: 11/F, Tower B, Global Trade Center, No.36 North Third Ring Road East, Dongcheng District, Beijing, 100013, PRC Tel: 010-52213236/7 www.junzhilawyer.com 回购注销 2021 年限制性股票激励计划部分限制性股票 及调整回购价格与回购数量之法律意见书 君致法字 2025295 号 致：山东新华医疗器械股份有限公司 北京市君致律师事 ...

Core Viewpoint - Xinhua Medical (600587.SH) has recently received the Medical Device Registration Certificate from the Shandong Provincial Drug Administration for two products: Interleukin-6 Test Kit (Quantum Dot Fluorescence Immunochromatography Method) and Procalcitonin/Interleukin-6 Dual Test Kit (Quantum Dot Fluorescence Immunochromatography Method) [1] Group 1 - The company has obtained regulatory approval for new medical testing products [1] - The approved products utilize advanced quantum dot fluorescence immunochromatography technology [1] - This development may enhance the company's product portfolio in the medical device sector [1]

截至发稿，新华医疗市值为88亿元。 每经头条（nbdtoutiao）——直击茅台经销商大会：2000多人周末齐聚！重大变革公布：涉及茅台酒价 格、分销等，董事长陈华：经销商不能再"躺着赚钱" （记者 曾健辉） 每经AI快讯，新华医疗（SH 600587，收盘价：14.54元）12月29日晚间发布公告称，山东新华医疗器械 股份有限公司于近日收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》。包括"白 介素6检测试剂盒"等产品。 2024年1至12月份，新华医疗的营业收入构成为：医疗器械占比68.46%，制药装备占比21.66%，医疗服 务占比8.32%，其他业务占比1.56%。 ...